- Home
- SCLX vs INO Comparison
SCLX vs INO Comparison
Compare SCLX & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLX
- INO
- Stock Information
- Founded
- SCLX 2011
- INO 1979
- Country
- SCLX United States
- INO United States
- Employees
- SCLX N/A
- INO 122
- Industry
- SCLX Biotechnology: Pharmaceutical Preparations
- INO Medical/Dental Instruments
- Sector
- SCLX Health Care
- INO Health Care
- Exchange
- SCLX Nasdaq
- INO Nasdaq
- Market Cap
- SCLX 130.1M
- INO 110.7M
- IPO Year
- SCLX N/A
- INO 1998
- Fundamental
- Price
- SCLX $0.61
- INO $4.30
- Analyst Decision
- SCLX Strong Buy
- INO Buy
- Analyst Count
- SCLX 3
- INO 6
- Target Price
- SCLX $11.33
- INO $21.00
- AVG Volume (30 Days)
- SCLX 184.3K
- INO 320.4K
- Earning Date
- SCLX 11-26-2024
- INO 11-14-2024
- Dividend Yield
- SCLX N/A
- INO N/A
- EPS Growth
- SCLX N/A
- INO N/A
- EPS
- SCLX N/A
- INO N/A
- Revenue
- SCLX $50,833,000.00
- INO $203,413.00
- Revenue This Year
- SCLX $32.77
- INO N/A
- Revenue Next Year
- SCLX $50.71
- INO N/A
- P/E Ratio
- SCLX N/A
- INO N/A
- Revenue Growth
- SCLX 9.41
- INO N/A
- 52 Week Low
- SCLX $0.54
- INO $4.20
- 52 Week High
- SCLX $2.63
- INO $14.75
- Technical
- Relative Strength Index (RSI)
- SCLX 28.71
- INO 23.84
- Support Level
- SCLX $0.73
- INO $5.25
- Resistance Level
- SCLX $1.14
- INO $5.60
- Average True Range (ATR)
- SCLX 0.11
- INO 0.27
- MACD
- SCLX -0.04
- INO -0.08
- Stochastic Oscillator
- SCLX 11.99
- INO 1.11
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.